Twist has raised more than $363 million in equity financing, most recently a $291.5 million Series D round that closed in July, according to the prospectus. DNA synthesis firm Twist Bioscience has secured $70m from its initial public offering (IPO), selling five million shares at $14 each. The company has developed a proprietary technology that manufactures synthetic DNA by “writing” it on a silicon chip, which it claims makes DNA synthesis scalable and less expensive than using traditional techniques. In the US, where companies are allowed to sell their own products without disclosing how they do it, there is no requirement for such disclosure.
DNA synthesis firm Twist Bioscience has secured $70m from its initial public offering (IPO), selling five million shares at $14 each. The company has developed a proprietary technology that manufactures synthetic DNA by “writing” it on a silicon chip, which it claims makes DNA synthesis scalable and less expensive than using traditional techniques. In the US, where companies are allowed to sell their own products without disclosing how they do it, there is no requirement for such disclosure.